Ardelyx, INC Form 4 insider transactions

Elizabeth Grammer, Chief Legal and Administrative Officer of Ardelvx, Inc., reported the sale of 4,291 shares of common stock on February 20, 2025, to cover withholding taxes related to the vesting of restricted stock units.

Ardelux CEO Michael Raab exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director David Mott of Ardelux, Inc. purchased 199,000 shares of common stock at a price of $4.9883 per share on January 21, 2025.

Director Richard J. Rodgers exercised stock options to acquire 100,000 shares of Ardelux, Inc. at a price of $0.55 per share.

Michael Raab, CEO of Ardelvx, reports the sale and acquisition of common stock and stock options, including transactions made under a 10b5-1 trading plan.

Director David Mott of Ardelux, Inc. exercised stock options to acquire 100,000 shares of common stock at $0.55 per share.

Director David Mott purchased 213,300 shares of Ardelyx, Inc. common stock at an average price of $4.6722 on December 19, 2024.

Ardelxy CEO Michael Raab sold 25,000 shares of common stock at a weighted average price of $5.2648, while also acquiring 25,000 shares at $0.99, both under a pre-arranged 10b5-1 trading plan.

Ardelux CEO Michael Raab sold 25,000 shares of common stock at an average price of $5.3793 per share, according to a recent SEC filing.

Laura A. Williams, Chief Medical Officer of Ardelyx, Inc., sold 7,366 shares of common stock to cover taxes upon the vesting of restricted stock units.

Ardelux's Chief Development Officer, David P. Rosenbaum, sold shares to cover taxes following the vesting of restricted stock units.

Ardelyx's Chief Financial Officer, Justin Renz, sold 5,260 shares of common stock to cover taxes following the vesting of restricted stock units.

Ardelux CEO Michael Raab sold 31,980 shares of common stock to cover taxes following the vesting of restricted stock units.

Elizabeth Grammer, Chief Legal and Administrative Officer at Ardelix, sold 7,046 shares of common stock to cover taxes upon the vesting of restricted stock units.

Robert Blanks, Chief Regulatory and Quality Affairs Officer at Ardelux Inc., sold 4,941 shares of common stock to cover taxes upon the vesting of restricted stock units.

Director David Mott of Ardelix, Inc. purchased 215,868 shares of common stock at a weighted average price of $4.6167 per share.

Ardelix CEO Michael Raab sold 2,743 shares of common stock at $4.90 per share under a pre-arranged 10b5-1 trading plan.

Chief Development Officer David P. Rosenbaum reports exercising stock options and selling shares of Ardelix, Inc. common stock.

David P. Rosenbaum, Chief Development Officer of Ardelvx, Inc., reports the acquisition and disposal of common stock and derivative securities.

Ardelix's CEO, Michael Raab, exercised stock options and sold 25,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Ardelix's CEO, Michael Raab, sold 7,500 shares of common stock at $6.01 per share on October 11, 2024, under a pre-arranged 10b5-1 trading plan.

David Rosenbaum, Chief Development Officer of Ardelvx, Inc., reports the sale of common stock under a pre-arranged 10b5-1 trading plan.

Ardelix's President and CEO, Michael Raab, executed a sale of 3,000 common stock shares at $6.07 per share under a pre-arranged 10b5-1 trading plan.

David Rosenbaum, Chief Development Officer of Ardelyx, Inc., sold 5,312 shares of common stock at an average price of $6.2601.

Ardelyx's CEO, Michael Raab, exercised stock options and sold 35,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Ardelix, Inc.'s CEO, Michael Raab, sold 7,500 shares of common stock at an average price of $6.218 per share on August 27, 2024, under a pre-arranged 10b5-1 trading plan.

Laura A. Williams, Chief Medical Officer of Ardelix, Inc., sold 7,412 shares of common stock on August 20, 2024, to cover withholding taxes related to the vesting of restricted stock units.

David P. Rosenbaum, Chief Development Officer of Ardelyx, Inc., sold shares of common stock to cover withholding taxes upon the vesting of restricted stock units.

Ardelvx CFO Justin Renz sold 5,289 shares of common stock on August 20, 2024, to cover withholding taxes related to the vesting of restricted stock units.

Michael Raab, CEO of Ardelvx, Inc., sold 32,225 shares of common stock on August 20, 2024, to cover withholding taxes related to the vesting of restricted stock units.